Skip to research
Margin Monkey THEMARGINMONKEY Start my free trialTry free

Teva- Pharmaceutical Industries (TEVA) stock in plain English

Free brief · no signupStart here
TEVAPublished Nov 7, 2026
Teva- Pharmaceutical Industries Ltd
Healthcare · Drug Manufacturers - Specialty & Generic
Produces generic prescription pharmaceuticals, active pharmaceutical ingredients, and proprietary specialty medicines.
Assets:
37 manufacturing sitesproducing billions of dosage units annually worldwide
37,000 employeesworking across commercial operations and research facilities globally
Active ingredient businesssupplies pharmaceutical chemicals to internal and external drugmakers
Locked assetIn the full report
Rated Nov 19, 2026

Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.

25
OPS ScoreOperating finances
Latest quote
-8.74%$38.54
$44.97B
90.8×
$17.23B

Change shown by the quote provider. Data may be delayed.

Financial statements, in plain wordsSales, profit, debt and cash, year by year
Published Nov 07, 2026Quotes updated Nov 20, 04:05 UTCOPS Score, TMM Score and the rating are research summaries, not advice or forecasts.
That was TEVA. The desk has 1,900+ more companies.Each one comes with its scores, its flags and the sources behind them.
7 days free · No card

What does Teva- Pharmaceutical Industries (TEVA) do?

Teva- Pharmaceutical Industries Ltd (TEVA) is a U.S.-listed company in Healthcare (Drug Manufacturers - Specialty & Generic). What it does: Produces generic prescription pharmaceuticals, active pharmaceutical ingredients, and proprietary specialty medicines. Manufactures and distributes the world's largest portfolio of generic medications alongside proprietary specialty. It is worth $44.97B on the market and sold $17.23B over the last year.

Market cap
$44.97B
P/E ratio
90.8×
Annual sales
$17.23B
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Brief updated
Nov 07, 2026

Brands and businesses behind TEVA

  • Austedo: Sells prescription tablets treating chorea associated with Huntington disease and tardive dyskinesia.
  • Ajovy: Sells injectable preventive migraine treatments directly through healthcare providers and specialty pharmacies.
  • Copaxone: Generates revenue selling daily and thrice-weekly injections for relapsing forms of multiple sclerosis.
  • Uzedy: Earns sales from an extended-release injectable suspension used to treat schizophrenia in adults.
  • ProAir: Generates revenue through prescription inhalation aerosol treatments for bronchospasm in asthma patients.

TEVA’s flags, in plain English

Each flag is a number from Teva- Pharmaceutical Industries’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 07, 2026.

Wide Gross Margin

Gross margin of 53.5% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.

Cheap on Cash Flow

Priced at 17.2 times the cash it generates each year. The share price is low compared with the cash the business actually brings in, and cash is harder to dress up than profit.

Debt Is Driving

Heavy debt, 213% of shareholder equity. The company owes a lot compared with what it earns. Lenders get paid before shareholders, which leaves management fewer options in a weak year.

2 more risk notes open with the free trial. Try it free for 7 days.

Questions about TEVA

How big is Teva- Pharmaceutical Industries?

Teva- Pharmaceutical Industries’ market cap is $44.97B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $17.23B: what customers paid the company over the last year, before any costs.

What is TEVA’s P/E ratio?

TEVA’s P/E ratio is 90.8×. Investors pay about 90.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.

What could go wrong with TEVA?

The company carries approximately 19 billion dollars in debt accumulated from historical acquisitions. That is one risk on Teva- Pharmaceutical Industries’ card. Its first risk flag is Debt Is Driving, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.

Where do these numbers come from?

From Teva- Pharmaceutical Industries’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TEVA’s filings on SEC.gov. The Margin Monkey is research, not advice.

Your first 7 days are free.Search all 1,900+ companies and open every card. Members also get the ratings, Picks and the TMM Score.
7 days free · No card